Packaging, Labeling & Serialization

Contract packagers and serialization providers — controlling labeling accuracy, tamper evidence, and DSCSA/FMD track-and-trace across the supply chain.

Assess your quality system →Explore GxP disciplines →
WHAT THIS SECTOR DOES

Contract packagers and serialization providers apply the labelling, tamper evidence, and unique identifiers that turn bulk product into a dispensable, traceable unit. Labelling accuracy and serialization integrity are patient-safety controls: a mislabel or a broken code can send the wrong medicine to a patient or let a falsified one into the supply chain.

REGULATORY LANDSCAPE

Packaging and labelling operations follow GMP labelling controls — FDA 21 CFR 211 subpart G and tamper-evident requirements at 211.132. Serialization is driven by the EU Falsified Medicines Directive (2011/62/EU) and its Delegated Regulation (2016/161) and by the US Drug Supply Chain Security Act (DSCSA), with GS1 standards for the data carriers, all running on validated (Annex 11 / Part 11) systems.

THE OVERSIGHT MODEL

The MAH/manufacturer owns the artwork, the specification, and release; the contract packager executes to that specification under a Quality Agreement and is accountable for reconciliation, line clearance, and serialization data exchange. Because a labelling error is a leading cause of recalls, the split of responsibility for artwork control and code generation must be explicit and tightly controlled.

80
Standards decoded
3
GxP disciplines
WHAT QUALITY MEANS HERE
01

Labelling accuracy & line clearance

Artwork control, line clearance, and reconciliation that prevent mix-ups and mislabelling — a top source of packaging recalls.

02

Serialization & aggregation

Generating, applying, and verifying unique identifiers and aggregation data to meet FMD and DSCSA track-and-trace obligations.

03

Tamper evidence

Tamper-evident features and their verification (21 CFR 211.132 / FMD anti-tampering device) that let the end user trust the pack was not opened.

04

Validated serialization systems

Level 1–5 serialization systems validated under Annex 11 / 21 CFR Part 11, exchanging data reliably with partners and regulators.

GXP DISCIPLINES IN THIS SECTOR
GMPGood Manufacturing PracticeGDPGood Distribution PracticeCSVComputerised System Validation
STANDARDS SPEQ DECODES · 80
Open the full library →
21 CFR Part 211FDAHIGH INSPECTION RISK
Current Good Manufacturing Practice for Finished Pharmaceuticals
21 CFR Part 11FDAHIGH INSPECTION RISK
Electronic Records; Electronic Signatures
21 CFR Part 210FDA
Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs — General
21 CFR Part 820FDAHIGH INSPECTION RISK
Quality System Regulation (QSR) for Medical Devices
FDA Aseptic Processing GuidanceFDAHIGH INSPECTION RISK
Guidance for Industry — Sterile Drug Products Produced by Aseptic Processing
FDA Process Validation Guidance (2011)FDA
Guidance for Industry — Process Validation: General Principles and Practices
EU GMP Annex 1 (2022)EMAHIGH INSPECTION RISK
Manufacture of Sterile Medicinal Products
EU GMP Annex 11EMAHIGH INSPECTION RISK
Computerised Systems
EU GMP Annex 15EMA
Qualification and Validation
EU GMP Annex 2EMA
Manufacture of Biological Active Substances and Medicinal Products for Human Use
ICH Q5A(R2)ICH
Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin
ICH Q9(R1)ICH
Quality Risk Management
ICH Q10ICH
Pharmaceutical Quality System
ICH Q8(R2)ICH
Pharmaceutical Development
ICH Q11ICH
Development and Manufacture of Drug Substances (Chemical and Biotechnological/Biological Entities)
ICH Q12ICH
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q7ICH
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
USP <1116>USPHIGH INSPECTION RISK
Microbiological Control and Monitoring of Aseptic Processing Environments
USP <1117>USP
Microbiological Best Laboratory Practices
USP <1058>USP
Analytical Instrument Qualification
USP <61>/<62>USP
Microbiological Examination of Nonsterile Products
ISO 14644-1ISO
Cleanrooms and Associated Controlled Environments — Classification of Air Cleanliness by Particle Concentration
ISO 14644-2ISO
Cleanrooms and Associated Controlled Environments — Monitoring to Provide Evidence of Cleanroom Performance
ISO 9001:2015ISO
Quality Management Systems — Requirements
ISO 13485:2016ISO
Medical Devices — Quality Management Systems — Requirements for Regulatory Purposes
ISPE GAMP 5 (2022)ISPE
Good Practice Guide: Compliant GxP Computerised Systems
PIC/S PE 009-16PIC/S
Guide to Good Manufacturing Practice for Medicinal Products
2013/C 343/01ECHIGH INSPECTION RISK
EU Guidelines on Good Distribution Practice of Medicinal Products
WHO TRS 957, Annex 5WHO
WHO Good Distribution Practices for Pharmaceutical Products
MHRA GDPMHRA
UK Good Distribution Practice (Rules & Guidance for Distributors)
MHLW Ordinance No. 179PMDA
Japan GMP for Drugs and Quasi-drugs
ANVISA RDC 658/2022ANVISA
Brazilian Good Manufacturing Practices for Medicines
NOM-059-SSA1-2015COFEPRIS
Mexican Good Manufacturing Practices for Medicines
ANMAT Disposición 4159/2023ANMAT
Argentine GMP Guide for Medicines
Resolución 1160 de 2016INVIMA
Colombian Good Manufacturing Practices for Medicines
DS 021-2018-SADIGEMID
Peruvian GMP Manual for Pharmaceutical Products
Norma Técnica N° 127ISP Chile
Chilean Good Manufacturing Practices
China GMP (2010 Revision)NMPA
Good Manufacturing Practice for Drugs (China)
Revised Schedule M (2023)CDSCO
India GMP — Schedule M, Drugs and Cosmetics Rules
Health Canada GUI-0001Health Canada
Good Manufacturing Practices Guide for Drug Products
TGA Manufacturing PrinciplesTGA
Australian GMP — Manufacturing Principles (PIC/S Guide)
PDA TR No. 22PDA
Process Simulation for Aseptically Filled Products
ICH Q3D(R2)ICH
Guideline for Elemental Impurities
ASTM E2500ASTM
Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment
ISPE Baseline Guide Vol. 5 (2019)ISPE
Commissioning and Qualification (Second Edition)
MHRA GxP DI (2018)MHRAHIGH INSPECTION RISK
MHRA 'GxP' Data Integrity Guidance and Definitions
PIC/S PI 041-1PIC/SHIGH INSPECTION RISK
Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments
WHO GCLP (2009)WHO
Good Clinical Laboratory Practice (GCLP)
21 CFR Part 117FDAHIGH INSPECTION RISK
Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food
21 CFR Part 111FDAHIGH INSPECTION RISK
Current Good Manufacturing Practice for Dietary Supplements
Codex CXC 1-1969Codex
General Principles of Food Hygiene
21 CFR Part 226FDA
Current Good Manufacturing Practice for Type A Medicated Articles
21 CFR Part 225FDA
Current Good Manufacturing Practice for Medicated Feeds
Regulation (EU) 2019/6EC
Veterinary Medicinal Products
ISO 22716:2007ISO
Cosmetics — Good Manufacturing Practices (GMP): Guidelines on Good Manufacturing Practices
21 CFR Part 1271FDA
Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
21 CFR Part 606FDA
Current Good Manufacturing Practice for Blood and Blood Components
IEC 62304:2006+A1:2015IEC
Medical Device Software — Software Life Cycle Processes
21 CFR Part 1, Subpart LFDA
Foreign Supplier Verification Programs (FSVP)
21 CFR Part 121FDA
Mitigation Strategies to Protect Food Against Intentional Adulteration
21 CFR Part 507FDA
Current Good Manufacturing Practice and Preventive Controls for Food for Animals
VICH GL3(R)VICH
Stability Testing of New Veterinary Drug Substances and Medicinal Products
21 CFR Part 700FDA
Cosmetics — General
FD&C Act §503AFDAHIGH INSPECTION RISK
Pharmacy Compounding — Conditions for Exemption
FD&C Act §503BFDAHIGH INSPECTION RISK
Outsourcing Facilities — Registration and cGMP
USP <795>USPHIGH INSPECTION RISK
Pharmaceutical Compounding — Nonsterile Preparations
USP <797>USPHIGH INSPECTION RISK
Pharmaceutical Compounding — Sterile Preparations
USP <800>USPHIGH INSPECTION RISK
Hazardous Drugs — Handling in Healthcare Settings
State Pharmacy Practice ActsState Boards of PharmacyHIGH INSPECTION RISK
State Pharmacy Practice Acts and Compounding Regulations
21 CFR Part 1301DEA
Registration of Manufacturers, Distributors and Dispensers of Controlled Substances
21 CFR Part 1304DEA
Records and Reports of Registrants
Ph. Eur.EDQMHIGH INSPECTION RISK
European Pharmacopoeia
CEP (EDQM Certification)EDQM
Certificate of Suitability to the Monographs of the European Pharmacopoeia
IMDRF/SaMD WG/N10IMDRF
Software as a Medical Device (SaMD): Key Definitions
IMDRF/SaMD WG/N12IMDRF
SaMD: Possible Framework for Risk Categorization and Corresponding Considerations
IPEC-PQG GMP Guide (v5, 2022)IPECHIGH INSPECTION RISK
Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients
ISO/IEC 17025:2017ISO
General requirements for the competence of testing and calibration laboratories
ILAC MRAILAC
ILAC Mutual Recognition Arrangement
DSCSA (FD&C Act §§581–585)FDAHIGH INSPECTION RISK
Drug Supply Chain Security Act
GS1 General SpecificationsGS1
GS1 General Specifications — identification keys, data attributes and barcodes
WHERE QUALITY FAILS
  • Mislabelling or product mix-ups from weak line clearance and reconciliation
  • Serialization data errors that break aggregation or regulatory reporting
  • Tamper-evidence features missing or not verified
  • Serialization systems that fail validation or lose data in partner exchange
KEY REGULATORY BODIES
FDAEMAICHUSPISOISPEPIC/SECWHOMHRAPMDAANVISACOFEPRISANMATINVIMADIGEMIDISP ChileNMPACDSCOHealth CanadaTGAPDAASTMCodexIECVICHState Boards of PharmacyDEAEDQMIMDRFIPECILACGS1

Derived from the 80 standards SPEQ decodes for this sector.

REGULATED INDUSTRIES
The product industries this sector serves →
THE SPEQ FRAMEWORK
Regulatory intelligence → execution → maturity →
Weekly Briefing

Intelligence for Packaging, Labeling & Serialization

The enforcement actions, guidance, and quality signals that shape sponsor–provider oversight — curated for Packaging, Labeling & Serialization and delivered free each week.

Read a past issue →